Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 12/20 | 0.48 |
| ▸ | CCR3 | P51677 | 12/20 | 0.48 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.46 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22174094 | 0.91 | HRH1 (0.48) | HRH1CCR3TEAD1TEAD3KCNH2 | |
| SCHEMBL22174139 | 0.86 | KCNH2 (0.46) | TEAD1TEAD3KCNH2EPHX2CYP2C9 | |
| SCHEMBL22446393 | 0.85 | EGFR (0.52) | TEAD1TEAD3SCD5EPHX2EGFR | |
| SCHEMBL22446324 | 0.85 | EPHX2 (0.46) | HRH1CCR3TEAD1TEAD3KCNH2 | |
| SCHEMBL22174221 | 0.84 | BTK (0.53) | TEAD1TEAD3SCD5EGFR | |
| SCHEMBL22174220 | 0.84 | BTK (0.52) | HRH1CCR3TEAD1TEAD3KCNH2 | |
| SCHEMBL22174118 | 0.83 | EPHX2 (0.58) | TEAD1TEAD3SCD5EPHX2EGFR | |
| SCHEMBL22446335 | 0.82 | EGFR (0.52) | TEAD1TEAD3EPHX2EGFRERBB2 | |
| SCHEMBL22173959 | 0.82 | EPHX2 (0.59) | TEAD1TEAD3SCD5EPHX2EGFR | |
| SCHEMBL22173949 | 0.79 | EPHX2 (0.58) | HRH1TEAD1TEAD3EPHX2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | HRH1 4569/4885CCR3 1977/4885TEAD1 3992/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | HRH1 4198/4885CCR3 1749/4885TEAD1 4235/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | HRH1 4569/4885CCR3 1977/4885TEAD1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.